Chengdu, China

Dixiang Luo

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Dixiang Luo: Innovator in Recombinant Fusion Proteins

Introduction

Dixiang Luo is a prominent inventor based in Chengdu, China. He has made significant contributions to the field of biotherapeutics, particularly in the development of recombinant fusion proteins. With a total of 2 patents, his work focuses on innovative solutions for treating various diseases.

Latest Patents

Dixiang Luo's latest patents include a groundbreaking invention related to human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof. This invention involves a recombinant fusion protein that comprises a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone. The method outlined in the patent aims to treat diseases or conditions in subjects by administering a therapeutically effective amount of the recombinant fusion protein or a pharmaceutical composition containing it.

Career Highlights

Throughout his career, Dixiang Luo has worked with notable companies in the biotherapeutics sector, including Salubris Biotherapeutics, Inc. and Salubris (Chengdu) Biotech Co., Ltd. His expertise in recombinant proteins has positioned him as a key player in the development of innovative therapeutic solutions.

Collaborations

Dixiang has collaborated with esteemed colleagues such as John H Li and Shengwei Li. These partnerships have further enhanced his research and development efforts in the field of biotherapeutics.

Conclusion

Dixiang Luo's contributions to the field of recombinant fusion proteins demonstrate his commitment to advancing medical science. His innovative patents and collaborations highlight his role as a leading inventor in biotherapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…